Rapid Readouts: Phase 3 ASCENT Study for Metastatic Triple-Negative Breast Cancer
August 11th 2021Hope S. Rugo, MD, FASCO, discusses data presented at the 2021 American Society of Clinical Oncology annual meeting from the phase 3 ASCENT study of patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan.
Read More
Future Directions for the Management of HR+ Breast Cancer
August 11th 2021Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.
Read More
Using CDK4/6 Inhibitors After HR+ mBC Disease Progression
July 21st 2021Breast cancer experts comment on whether there is a benefit to switching to or continuing on CDK4/6 inhibitors with disease progression for HR+ metastatic breast cancer and discuss the use of tamoxifen for third-line endocrine therapy.
Read More